Suprachoroidal Injection of Triamcinolone Acetonide for Management of Diabetic Macular Edema

  • days left to enroll
  • participants needed
  • sponsor
    Azza Mohamed Ahmed Said
Updated on 23 January 2021


Intravitreal triamcinolone acetonide is a well-known method of treatment of diabetic macular edema, however, it has many side effects, most commonly causing cataract and glaucoma. Suprachoroidal route is an emerging route of delivery of intraocular drugs.

This is to our knowledge the first prospective study to compare the effect of triamcinolone acetonide delivered via the intravitreal versus the suprachoroidal route in the treatment of diabetic macular edema as regards safety and efficacy.


The purposes of this study were:

  1. To compare between intravitreal and suprachoroidalTA injection for treatment of DME in terms of improvement in both best corrected visual acuity (BCVA) and central macular thickness (CMT), and development of complications.
  2. To identify which dose of TA will be efficient using the suprachoroidal route.
    • Type of Study: A prospective interventional randomized comparative study.
    • Study setting:Ophthalmology Department, Ain Shams University.
    • Study period:2 years.
    • Study population: Patients having DME.
    • Sample size: The study will be conducted on 45 eyes. This was done using PASS program, setting alpha error at 5% and power at 80%. Results from previous study (Koc et al., 2017) showed that the mean improvement in BCVA after 6 months of intravitreal injection of TA was 4.6 8.8. While it is assumed to be 12.6 and 14.6 for the low dose and high dose suprachoroidal route.
    • Ethical considerations: Explanation of the procedure will be done for all patients and an informed written consent will be taken. Ethics committee approval will be obtained from the Institutional Review Board of the Faculty of Medicine, Ain Shams University.

All patients will undergo the following at initial presentation:

  • Careful history taking.
  • Full ophthalmological assessment including:

Baseline BCVA. Anterior segment examination using slit lamp biomicroscopy. IOP measurement using Goldmann applanation tonometer. Posterior segment examination using binocular indirect ophthalmoscopy and indirect slit lamp biomicroscopy (+90D Volk lens) for detailed evaluation of the macula and optic nerve head.

Fundus photography using VX-20 Kowa fundus camera, Japan. Ultrasound biomicroscopy (UBM) for measurement of scleral thickness in groups (II) and (III)using VuMax, Sonomed Escalon, theUnited States of America.

Spectral domain optical coherence tomography (SD-OCT) imaging using Retinascan RS 3000 advance, Nidek, Gamgori, Japan.

Examination protocol: Macular map and 12 radial line scans to determine central macular thickness (1mm) and macular thickness in the inner 3 and 6 mm rings divided each into four quadrants.

Duration of follow up: 6 months.

Follow up schedule:

Follow up visits will be done at 1 day, 1 week, 1 month,3 months and 6 months.During the follow up, the following will be done:

  • BCVA measurement.
  • Full ophthalmological examination.
  • Fundus photography after six months of injection.
  • CMT measurement using SD-OCT at 1,3 and 6 months post-injection. In case of resistance to treatment (worsening of BCVA or CMT, or persistence of macular edema with central thickness less than 300m), reinjection will be considered using the same drug and/or anti-VEGF agents.

Condition Safety, Efficacy
Treatment Intravitreal injection (4mg/0.1ml), Superachoroidal injection (4 mg/0.1ml), Suprachoroidal injection (2mg/0.1ml)
Clinical Study IdentifierNCT04069780
SponsorAzza Mohamed Ahmed Said
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Type-II Diabetes Mellitus patients
Centrally involving DME with central thickness<300m with no vitreomacular traction
Recently diagnosed DME or received treatment for DME in more than six months

Exclusion Criteria

Pre-existingretinal disease other than diabetic retinopathy
Diabetic macular ischemia
IOP 21 mmHg and/or asymmetrical cup disc ratio or glaucoma patients
Prior cataract extraction of less than six months
Opaque media, uncooperative patients or patients with poor fixation
Any uncontrolled systemic disease
Systemic or local medicationsthat might affect the macular thickness
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note